β受体阻滞剂对开放腹主动脉瘤修复术后死亡率的影响
该回顾性研究基于Premier医疗数据库2009年第三季度至2015年第一季度接受开放腹主动脉瘤修复术的患者,评估围术期β受体阻滞剂使用与术后院内死亡率的关系。结果显示,β受体阻滞剂使用与术后死亡率显著降低相关,且呈现剂量-反应关系。
要点
- 围术期β受体阻滞剂使用与开放腹主动脉瘤修复术后院内死亡率降低相关。
- β受体阻滞剂使用者主要不良事件发生率更高,但失败救援率更低。
- β受体阻滞剂与术后死亡率的关系呈现剂量-反应关系。
核心结论
- 围术期β受体阻滞剂使用与开放腹主动脉瘤修复术后院内死亡率显著降低相关。
研究设计与样本
- 回顾性研究,使用Premier医疗数据库2009年第三季度至2015年第一季度接受开放腹主动脉瘤修复术的患者数据。
- 共纳入6515例患者,排除45岁以下、创伤后入院或接受多次主动脉修复手术者。
主要发现
- 6515例患者中5423例(83.2%)接受围术期β受体阻滞剂。
- β受体阻滞剂使用者主要不良事件发生率45.6%,未使用者35.2%(P < 0.001)。
- β受体阻滞剂使用者失败救援率7.6%,未使用者19.5%(P < 0.001)。
- 多变量逻辑回归模型中,无冠心病史患者使用β受体阻滞剂与死亡率降低57%相关(OR 0.43,95%CI 0.31-0.56,P = 0.001)。
- 有冠心病史患者使用β受体阻滞剂与死亡率降低81%相关(OR 0.19,95%CI 0.11-0.31,P < 0.001)。
临床怎么用
- 围术期使用β受体阻滞剂可能降低开放腹主动脉瘤修复术后院内死亡率,尤其对冠心病史患者获益更明显。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the effect of perioperative beta blocker (BB) use on postoperative in-hospital mortality after open repair of abdominal aortic aneurysm (OAR). BACKGROUND: Postoperative mortality after OAR ranges from 3.0% to 4.5%. Insight about the effect of BBs on postoperative mortality after OAR is currently lacking. METHODS: This is a retrospective study of patients undergoing OAR from 2009-Q3 to 2015-Q1 in the Premier Healthcare Database. The Premier Healthcare Database includes data representing 20% of all inpatient US discharges annually. Patients under 45 years, admitted after a trauma or who underwent multiple aortic repair procedures, were excluded. Multivariable logistic regression models were created to assess the relationship between perioperative BB use and postoperative in-hospital mortality. RESULTS: Of 6515 patients admitted for OAR, 5423 (83.2%) received perioperative BBs. Patients who received BBs were more likely to develop major adverse events compared with those who did not (45.6% vs 35.2%; P < 0.001); however, failure to rescue was lower among BB users (7.6% vs 19.5%; P < 0.001). In a multivariable logistic regression model, BB use was associated with 57% [odds ratio 0.43, 95% confidence interval (CI) 0.31-0.56, P = 0.001) and 81% (odds ratio 0.19, 95% CI 0.11-0.31, P < 0.001) lower odds of mortality among patients without and with a history of coronary artery disease, respectively. The predicted mortality (95% CI) for patients who did not receive BBs, or received low, intermediate, or high-intensity BBs was 11.6% (8.0%-15.2%), 5.4% (4.4%-6.5%), 2.5% (1.9%-3.0%), and 3.3% (2.3%-4.3%), respectively. CONCLUSIONS: In-hospital use of BBs was associated with a significant reduction in postoperative mortality after OAR. This is the first study to demonstrate a dose-response relationship between BBs and postoperative mortality after OAR.
引用
- Alshaikh HN, Canner JK, Malas M, et al. Effect of Beta Blockers on Mortality After Open Repair of Abdominal Aortic Aneurysm. Ann Surg. 2018. PMID: 28486388. doi:10.1097/SLA.0000000000002291
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。